retatrutide clinical trial results retatrutide weight loss Results: 28.3% Data Retatrutide is getting a lot

Eli Lilly, which also makes the weight loss drugs Mounjaro and Zepbound, said it plans to complete seven additional phase 3 clinical trials of retatrutide in 2026, compiling data that will be submitted to the U.S

This helps to maintain the quality and efficacy of GLP-1 medicines

But certain symptoms may warrant a conversation with your provider sooner rather than later

34 Notably, some data suggest a potential risk signal among individuals concurrently using antidepressants or benzodiazepinesgroups already at elevated baseline psychiatric risk

It is important to note that some cancer treatments, including certain chemotherapy drugs and targeted therapies, may not be a good match with GLP-1 medications